As of November 2014, the European Medicines Agency (EMA) had received and assessed 29 applications as part of its pilot project on adaptive pathways, formerly known as adaptive licensing.
As of November 2014, the European Medicines Agency (EMA) had received and assessed 29 applications as part of its pilot project on adaptive pathways, formerly known as adaptive licensing. Nine of these applications had been selected for discussion with the applicant.
EMA launched its pilot project in March 2014 to explore this approach with real medicines in development. Stage I of the pilot scheme will close at the end of February 2015. Stage II of the project will include in-depth, face-to-face meetings with the applicants. After February 28, 2015, the agency will still consider new applications for stage II face-to-face meetings if they are well developed.
EMA is planning to publish a report on initial experience gained as part of the pilot project by the end of 2014. The agency recently changed the name of its pilot project from adaptive licensing to adaptive pathways to better reflect the idea of a life-span approach to bring new medicines to patients with clinical drug development, licensing, reimbursement, and utilization in clinical practice, and monitoring viewed as a continuum.
The concept of adaptive pathways foresees an early approval of a medicine for a restricted patient population based on small initial clinical studies, according to an article co-authored by members of the EMA and published in Clinical Pharmacology and Therapeutics. The first approval is followed by progressive adaptations of the marketing authorization to expand access to the medicine to broader patient populations based on data gathered from its use and additional studies.
Applicants should contact EMA at adaptivepathways@ema.europa.eu for advice on the content and suitability of their request to be considered for stage II of the pilot.
Read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.